We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Astrazeneca (AZN) Suffers a Larger Drop Than the General Market: Key Insights
Read MoreHide Full Article
Astrazeneca (AZN - Free Report) closed the most recent trading day at $192.30, moving -1.29% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.41%. Elsewhere, the Dow saw a downswing of 0.36%, while the tech-heavy Nasdaq depreciated by 0.89%.
The pharmaceutical's shares have seen an increase of 4.1% over the last month, surpassing the Medical sector's gain of 0.47% and falling behind the S&P 500's gain of 9.71%.
The investment community will be paying close attention to the earnings performance of Astrazeneca in its upcoming release. The company is slated to reveal its earnings on April 29, 2026. The company's earnings per share (EPS) are projected to be $2.57, reflecting a 3.63% increase from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $14.98 billion, indicating a 10.22% increase compared to the same quarter of the previous year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $10.31 per share and revenue of $63.03 billion. These totals would mark changes of +12.55% and +7.31%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Astrazeneca. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.07% lower. As of now, Astrazeneca holds a Zacks Rank of #3 (Hold).
From a valuation perspective, Astrazeneca is currently exchanging hands at a Forward P/E ratio of 18.9. This signifies a discount in comparison to the average Forward P/E of 21.22 for its industry.
Also, we should mention that AZN has a PEG ratio of 1.47. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.5 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 143, positioning it in the bottom 42% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Astrazeneca (AZN) Suffers a Larger Drop Than the General Market: Key Insights
Astrazeneca (AZN - Free Report) closed the most recent trading day at $192.30, moving -1.29% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.41%. Elsewhere, the Dow saw a downswing of 0.36%, while the tech-heavy Nasdaq depreciated by 0.89%.
The pharmaceutical's shares have seen an increase of 4.1% over the last month, surpassing the Medical sector's gain of 0.47% and falling behind the S&P 500's gain of 9.71%.
The investment community will be paying close attention to the earnings performance of Astrazeneca in its upcoming release. The company is slated to reveal its earnings on April 29, 2026. The company's earnings per share (EPS) are projected to be $2.57, reflecting a 3.63% increase from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $14.98 billion, indicating a 10.22% increase compared to the same quarter of the previous year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $10.31 per share and revenue of $63.03 billion. These totals would mark changes of +12.55% and +7.31%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Astrazeneca. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.07% lower. As of now, Astrazeneca holds a Zacks Rank of #3 (Hold).
From a valuation perspective, Astrazeneca is currently exchanging hands at a Forward P/E ratio of 18.9. This signifies a discount in comparison to the average Forward P/E of 21.22 for its industry.
Also, we should mention that AZN has a PEG ratio of 1.47. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.5 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 143, positioning it in the bottom 42% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.